Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2014

Open Access 01-12-2014 | Research article

Management of oral anticoagulation after cardioembolic stroke and stroke survival data from a population based stroke registry (LuSSt)

Authors: Frederick Palm, Martin Kraus, Anton Safer, Joachim Wolf, Heiko Becher, Armin J Grau

Published in: BMC Neurology | Issue 1/2014

Login to get access

Abstract

Background

Cardioembolic stroke (CES) due to atrial fibrillation (AF) is associated with high stroke mortality. Oral anticoagulation (OAC) reduces stroke mortality, however, the impact of OAC-administration during hospital stay post ischemic stroke on mortality is unclear. We determined whether the timing of OAC initiation among other prognostic factors influenced mortality after CES.

Methods

Within the Ludwigshafen Stroke Study (LuSSt), a prospective population-based stroke register, we analysed all patients with a first ever ischemic stroke or TIA due to AF from 2006 until 2010. We analysed whether treatment or non-treatment with OAC and initiation of OAC-therapy during and after hospitalization influenced stroke mortality within 500 days after stroke/TIA due to AF.

Results

In total 479 patients had a first-ever ischemic stroke (n = 394) or TIA (n = 85) due to AF. One-year mortality rate was 28.4%. Overall, 252 patients (52.6%) received OAC. In 181 patients (37.8%), OAC treatment was started in hospital and continued thereafter. Recommendation to start OAC post discharge was given in 110 patients (23.0%) of whom 71 patients received OAC with VKA (14.8%). No OAC-recommendation was given in 158 patients (33.0%). In multivariate Cox regression analysis, higher age (HR 1.04; 95% CI 1.02-1.07), coronary artery disease (HR: 1.6; 95% CI 1.1-2.3), higher mRS-score at discharge (HR 1.24; 95% CI 1.09-1.4), and OAC treatment ((no OAC vs started in hospital (HR: 5.4; 95% CI 2.8-10.5), were independently associated with stroke mortality. OAC-timing did not significantly influence stroke mortality (started post discharge vs. started in hospital (HR 0.3; 95% CI 0.07-1.4)).

Conclusions

OAC non-treatment is the main predictor for stroke mortality. Although OAC initiation during hospital stay showed a trend towards higher mortality, early initiation in selected patients is an option as recommendation to start OAC post hospital was implemented in only 64.5%. This rate might be elevated by implementation of special intervention programs.
Appendix
Available only for authorised users
Literature
1.
Hajat C, Heuschmann PU, Coshall C, Padayachee S, Chambers J, Rudd AG, Wolfe CD: Incidence of aetiological subtypes of stroke in a multi-ethnic population based study: the south London stroke register. J Neurol Neurosurg Psychiatry. 2011, 82 (5): 527-533. 10.1136/jnnp.2010.222919.CrossRefPubMed
2.
Palm F, Urbanek C, Wolf J, Buggle F, Kleemann T, Hennerici MG, Inselmann G, Hagar M, Safer A, Becher H, Grau AJ: Etiology, risk factors and sex-differences in ischemic stroke in the Ludwigshafen stroke study (LuSSt), a population-based stroke registry. Cerebrovasc Dis. 2012, 33 (1): 64-68. 10.1159/000333417.CrossRef
3.
Jickling GC, Stamova B, Ander BP, Zhan X, Liu D, Sison SM, Verro P, Sharp FR: Prediction of cardioembolic, arterial, and lacunar causes of cryptogenic stroke by gene expression and infarct location. Stroke. 2012, 43 (8): 2036-2041. 10.1161/STROKEAHA.111.648725.CrossRefPubMedPubMedCentral
4.
Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D’Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ: Lifetime risk for development of atrial fibrillation: the framingham heart study. Circulation. 2004, 110 (9): 1042-1046. 10.1161/01.CIR.0000140263.20897.42.CrossRefPubMed
5.
Naccarelli GV, Varker H, Lin J, Schulman KL: Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009, 104 (11): 1534-1539. 10.1016/j.amjcard.2009.07.022.CrossRefPubMed
6.
Hannon N, Sheehan O, Kelly L, Marnane M, Merwick A, Moore A, Kyne L, Duggan J, Moroney J, McCormack PM, Daly L, Fitz-Simon N, Harris D, Horgan G, Williams EB, Furie KL, Kelly PJ: Stroke associated with atrial fibrillation-incidence and early outcomes in the north Dublin population stroke study. Cerebrovasc Dis. 2010, 29 (1): 43-49. 10.1159/000255973.CrossRefPubMed
7.
Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU: Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke. 2001, 32 (12): 2735-2740. 10.1161/hs1201.100209.CrossRefPubMed
8.
Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, Glahn J, Brandt T, Hacke W, Diener HC: Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke. 2001, 32 (11): 2559-2566. 10.1161/hs1101.098524.CrossRefPubMed
9.
Agarwal S, Hachamovitch R, Menon V: Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. Arch Intern Med. 2012, 172 (8): 623-631. 10.1001/archinternmed.2012.121. discussion 631-623CrossRefPubMed
10.
Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P: Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke. 2012, 43 (12): 3298-3304. 10.1161/STROKEAHA.112.673558.CrossRefPubMed
11.
Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Marin F, Palareti G, Kirchhof P: Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the European heart rhythm association [EHRA], endorsed by the european society of cardiology [ESC] working group on thrombosis. Thromb Haemost. 2011, 106 (6): 997-1011. 10.1160/TH11-10-0690.CrossRefPubMed
12.
Paciaroni M, Agnelli G, Corea F, Ageno W, Alberti A, Lanari A, Caso V, Micheli S, Bertolani L, Venti M, Palmerini F, Biagini S, Comi G, Previdi P, Silvestrelli G: Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke. 2008, 39 (8): 2249-2256. 10.1161/STROKEAHA.107.510321.CrossRefPubMed
13.
McGrath ER, Kapral MK, Fang J, Eikelboom JW, O’Conghaile A, Canavan M, O’Donnell MJ: Which risk factors are more associated with ischemic stroke than intracerebral hemorrhage in patients with atrial fibrillation?. Stroke. 2012, 43 (8): 2048-2054. 10.1161/STROKEAHA.112.654145.CrossRefPubMed
14.
Palm F, Urbanek C, Rose S, Buggle F, Bode B, Hennerici MG, Schmieder K, Inselmann G, Reiter R, Fleischer R, Piplack KO, Safer A, Becher H, Grau AJ: Stroke incidence and survival in ludwigshafen am rhein, Germany: the Ludwigshafen stroke study (LuSSt). Stroke. 2010, 41 (9): 1865-1870. 10.1161/STROKEAHA.110.592642.CrossRefPubMed
15.
Hatano S: Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ. 1976, 54 (5): 541-553.PubMedPubMedCentral
16.
Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH: Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the european society of cardiology (ESC). Eur Heart J. 2010, 31 (19): 2369-2429. 10.1093/eurheartj/ehq278.CrossRefPubMed
17.
Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P: 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European heart rhythm association. Eur Heart J. 2012, 33 (21): 2719-2747. 10.1093/eurheartj/ehs253.CrossRefPubMed
18.
Banks JL, Marotta CA: Outcomes validity and reliability of the modified rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke. 2007, 38 (3): 1091-1096. 10.1161/01.STR.0000258355.23810.c6.CrossRefPubMed
19.
Goldstein LB, Bertels C, Davis JN: Interrater reliability of the NIH stroke scale. Arch Neurol. 1989, 46 (6): 660-662. 10.1001/archneur.1989.00520420080026.CrossRefPubMed
20.
Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G: National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003, 139 (2): 137-147. 10.7326/0003-4819-139-2-200307150-00013.CrossRefPubMed
21.
Kaarisalo MM, Immonen-Raiha P, Marttila RJ, Salomaa V, Kaarsalo E, Salmi K, Sarti C, Sivenius J, Torppa J, Tuomilehto J: Atrial fibrillation and stroke. Mortality and causes of death after the first acute ischemic stroke. Stroke. 1997, 28 (2): 311-315. 10.1161/01.STR.28.2.311.CrossRefPubMed
22.
Andersen KK, Olsen TS: Reduced poststroke mortality in patients with stroke and atrial fibrillation treated with anticoagulants: results from a danish quality-control registry of 22,179 patients with ischemic stroke. Stroke. 2007, 38 (2): 259-263. 10.1161/01.STR.0000254622.52483.03.CrossRefPubMed
23.
Leistner S, Benik S, Laumeier I, Ziegler A, Nieweler G, Nolte CH, Heuschmann PU, Audebert HJ: Secondary prevention after minor stroke and TIA - usual care and development of a support program. PLoS One. 2012, 7 (12): e49985-10.1371/journal.pone.0049985.CrossRefPubMedPubMedCentral
24.
Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE: Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke. 2012, 43 (7): 1795-1799. 10.1161/STROKEAHA.111.630731.CrossRefPubMedPubMedCentral
25.
Azoulay L, Dell’aniello S, Simon TA, Renoux C, Suissa S: Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. Eur Heart J. 2014, 35 (28): 1991-1887. 10.1093/eurheartj/eht499.CrossRef
26.
McGrath ER, Kapral MK, Fang J, Eikelboom JW, O’Conghaile A, Canavan M, O’Donnell MJ: Association of atrial fibrillation with mortality and disability after ischemic stroke. Neurology. 2013, 81 (9): 825-832. 10.1212/WNL.0b013e3182a2cc15.CrossRefPubMed
27.
Heyden S, Heiss G, Heyman A, Tyroler AH, Hames CG, Patzschke U, Manegold C: Cardiovascular mortality in transient ischemic attacks. Stroke. 1980, 11 (3): 252-255. 10.1161/01.STR.11.3.252.CrossRefPubMed
28.
29.
Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jorgensen C, Madsen JK, Hansen PR, Kober L, Torp-Pedersen C, Gislason GH: Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009, 374 (9706): 1967-1974. 10.1016/S0140-6736(09)61751-7.CrossRefPubMed
30.
van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE: Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 2002, 360 (9327): 109-113. 10.1016/S0140-6736(02)09409-6.CrossRefPubMed
31.
Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, Rosenzweig M, Lip GY: Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol. 2013, 61 (22): 2264-2273. 10.1016/j.jacc.2013.03.020.CrossRefPubMed
32.
Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, Tijssen JG, Van de Werf F, Wallentin L: Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011, 32 (22): 2781-2789. 10.1093/eurheartj/ehr113.CrossRefPubMed
33.
Uchino K, Hernandez AV: Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012, 172 (5): 397-402. 10.1001/archinternmed.2011.1666.CrossRefPubMed
34.
EAFT (european atrial fibrillation trial) study group. Lancet. 1993, 342 (8882): 1255-1262.
35.
Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, O’Donnell M, Hohnloser SH, Hankey GJ, Shestakovska O, Yusuf S: Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol. 2012, 11 (3): 225-231. 10.1016/S1474-4422(12)70017-0.CrossRefPubMed
Metadata
Title
Management of oral anticoagulation after cardioembolic stroke and stroke survival data from a population based stroke registry (LuSSt)
Authors
Frederick Palm
Martin Kraus
Anton Safer
Joachim Wolf
Heiko Becher
Armin J Grau
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2014
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-014-0199-7

Other articles of this Issue 1/2014

BMC Neurology 1/2014 Go to the issue

Research article

Physical activity and associated levels of disability and quality of life in people with multiple sclerosis: a large international survey

Case report

Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanercept

Research article

Gait in Huntington’s disease and the stride length-cadence relationship

Research article

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

Study protocol

The effect of obstructive sleep apnea and treatment with continuous positive airway pressure on stroke rehabilitation: rationale, design and methods of the TOROS study

Research article

Influence of morphology and hemodynamic factors on rupture of multiple intracranial aneurysms: matched-pairs of ruptured-unruptured aneurysms located unilaterally on the anterior circulation